隴神戎發(300534.SZ):2020年度淨利預降25%-50%
格隆匯 1 月 29日丨隴神戎發(300534.SZ)披露2020年度業績預吿,預計歸屬於上市公司股東的淨利潤639萬元—955萬元,同比下降25%-50%;扣除非經常性損益後的淨利潤217萬元—325萬元,同比下降40%-60%。業績變動原因如下:
1.報吿期,新型冠狀病毒肺炎疫情對公司上半年藥品經營,尤其是終端醫療機構的藥品銷售造成了重大影響,下半年公司狠抓營銷攻堅,堅持穩市場、補欠帳,實現了經營業績企穩向好,2020年全年藥品銷售收入較上年同期減少1006萬元;其他收益較上年同期減少460萬元;影響歸屬於上市公司股東的淨利潤減少。
2.報吿期內,非經常性損益對淨利潤的影響金額預計為454萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.